Optimistic
Last updated: 2026-07-06 16:43:07 ET
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
AbbVie (NYSE:ABBV – Get Free Report) had its target price boosted by analysts at Cantor Fitzgerald from $240.00 to $265.00 in a research report...
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
AMAT, MA, ABBV, VATE and BOF headline new research reports highlighting AI, payments, healthcare and microcap growth opportunities.
Eli Lilly and Company, AbbVie, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that develop, manufacture, and sell medi...
Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays a quarterly distribution from roughly 100 quality-screened U.S. dividend stocks. The fund holds $71.6 billion in assets at an expense ratio of just 0.06%, and it tracks the Dow Jones U.S. Dividend ...
Research Analysts’ downgrades for Sunday, July 5th: AbbVie (NYSE:ABBV) was downgraded by analysts at Wall Street Zen from a strong-buy rating to a buy rating. ACRES Commercial Realty (NYSE:ACR) was downgraded by analysts at Wall Street Zen fro...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE